tamibarotene has been researched along with reparixin in 1 studies
| Studies (tamibarotene) | Trials (tamibarotene) | Recent Studies (post-2010) (tamibarotene) | Studies (reparixin) | Trials (reparixin) | Recent Studies (post-2010) (reparixin) |
|---|---|---|---|---|---|
| 198 | 10 | 105 | 70 | 4 | 48 |
| Protein | Taxonomy | tamibarotene (IC50) | reparixin (IC50) |
|---|---|---|---|
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | 0.0031 | |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | 0.0354 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anan, J; Hijioka, M; Hisatsune, A; Ishibashi, H; Katsuki, H; Kurauchi, Y; Matsushita, H; Seki, T; Shudo, K | 1 |
1 other study(ies) available for tamibarotene and reparixin
| Article | Year |
|---|---|
Suppression of CXCL2 upregulation underlies the therapeutic effect of the retinoid Am80 on intracerebral hemorrhage in mice.
Topics: Animals; Benzoates; Cerebral Hemorrhage; Chemokine CXCL2; Cytokines; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Sulfonamides; Tetrahydronaphthalenes; Up-Regulation | 2014 |